What is PCOS?

Did you know that over one in ten female workers in Malaysia (12.6%) are affected by PCOS (Dashti et al., 2019)? PCOS stands for Polycystic ovary syndrome is a common endocrine disorder primarily affecting women of reproductive age. This syndrome is characterized by a complex interplay of reproductive and metabolic abnormalities (Hoeger et al., 2021). While it is widely known for its impact on fertility and menstrual irregularities, PCOS also encompasses significant metabolic disturbances, including insulin resistance, obesity, dyslipidemia, and an increased risk of type 2 diabetes and cardiovascular disease. These metabolic disorders contribute substantially to the long-term health burden associated with the syndrome, extending beyond reproductive concerns.

Given these multifaceted risks, proactive screening for metabolic complications in women with PCOS is essential for timely intervention and effective management. Early identification of metabolic abnormalities allows healthcare providers to implement targeted lifestyle modifications, pharmacological treatments, and ongoing monitoring to mitigate progression to more severe health outcomes. Thus, a comprehensive approach addressing both reproductive and metabolic aspects is critical to improving the overall prognosis and quality of life for women affected by PCOS.

Metabolic Risks in PCOS

Women with PCOS commonly exhibit a cluster of metabolic disturbances, including insulin resistance, obesity, dyslipidemia, and hypertension. These metabolic abnormalities significantly elevate the risk of developing type 2 diabetes mellitus and cardiovascular diseases, which are the leading causes of morbidity and mortality in this population (Davinelli et al., 2020). Insulin resistance, a hallmark of PCOS, impairs glucose uptake and metabolism, often leading to compensatory hyperinsulinemia, which exacerbates androgen excess and ovarian dysfunction (Parker et al., 2025). Concurrently, obesity, especially central adiposity, worsens insulin resistance and promotes inflammatory pathways, compounding the metabolic burden.

Importantly, these metabolic disorders can manifest even before the clinical symptoms of PCOS become apparent. This scenario suggests that metabolic screening should be considered early in women at risk. Dyslipidemia in PCOS typically involves elevated triglyceride levels, low high-density lipoprotein (HDL) cholesterol levels, and increased low-density lipoprotein (LDL) cholesterol levels, all of which contribute to atherosclerotic risk (Kim & Choi, 2013). In addtion, hypertension, another common comorbidity, may arise due to endothelial dysfunction and altered vascular reactivity associated with insulin resistance and obesity. Early identification and management of these metabolic risk factors are critical for preventing long-term complications in women with PCOS (Chandrasekaran & Sagili, 2018).

Importance of Proactive Screening

Screening for metabolic risk factors typically involves assessing key clinical and biochemical parameters, such as blood glucose levels, lipid profiles, blood pressure, body mass index (BMI), and waist circumference. These measures provide a comprehensive overview of an individual’s metabolic health status, enabling healthcare providers to detect early signs of conditions such as diabetes, dyslipidemia, hypertension, and obesity.

Early identification through screening facilitates timely lifestyle modifications and medical interventions, which can significantly reduce the progression to more severe metabolic disorders and associated complications. Moreover, systematic screening supports the development of personalized treatment plans by stratifying patients according to their risk profiles.

This targeted approach allows for more effective management tailored to individual needs, improving outcomes, and optimizing resource allocation. By integrating these screening parameters into routine clinical practice, healthcare systems can enhance preventive care strategies and promote long-term metabolic health in diverse populations with different ethnicities.

Target Groups for Screening

Women who should undergo proactive metabolic screening for PCOS include those diagnosed with the syndrome, individuals presenting with menstrual irregularities such as oligomenorrhea (infrequent menstrual periods), amenorrhea (absence of menstrual periods), or heavy menstrual bleeding, those showing other symptoms like hirsutism (excessive hair growth), acne, androgenic alopecia (hair thinning), obesity or central adiposity, and those with a family history of type 2 diabetes or metabolic syndrome (Chandrasekaran & Sagili, 2018).

Benefits of Early Detection

Effective management strategies that prevent or delay the onset of diabetes and cardiovascular complications are critical for improving the long-term health outcomes. By addressing risk factors early, such approaches reduce the burden of chronic diseases and enhance patients’ quality of life. These interventions often include lifestyle modifications, such as diet and exercise, as well as medical treatments tailored to individual risk profiles, which together help maintain metabolic balance and protect cardiovascular function.

In addition to the physical health benefits, such strategies improve both metabolic health and reproductive outcomes, highlighting their comprehensive impact. Empowering patients through education and personalized management plans fosters greater engagement and adherence, enabling them to make informed decisions about their health. This patient-centered approach not only supports sustained behavioral change but also optimizes clinical results by aligning treatment with each patient’s unique needs and circumstances.

Clinical Implementation and Challenges

Routine screening at the time of diagnosis and at regular intervals thereafter is essential for early detection and effective management of health conditions. This proactive approach enables timely identification of disease progression or complications, allowing for prompt intervention that can improve patient outcomes. Consistent screening protocols help standardize care, ensuring that patients receive comprehensive monitoring tailored to their specific risk profiles and clinical needs.

The involvement of multidisciplinary teams significantly enhances the quality of management by integrating diverse expertise and perspectives in patient care. Collaboration among specialists, primary care providers, and allied health professionals fosters holistic treatment plans and coordinated follow-up.

However, challenges such as patient awareness, accessibility to healthcare services, and cultural factors play a critical role in adherence to screening recommendations. Addressing these barriers through targeted education, improved healthcare infrastructure, and culturally sensitive communication is vital to maximizing screening uptake and ultimately improving health outcomes.

Reference

1. Chandrasekaran, S., & Sagili, H. (2018). Metabolic syndrome in women with polycystic ovary syndrome. The Obstetrician & Gynaecologist, 20(4), 245–252. https://doi.org/10.1111/tog.12519
2. Dashti, S., Abdul latiff,  latiffah, Abdul Hamid, H., Mohamad Saini, S., Shah Abu Bakar, A., Binti Sabri, N. A. I., Ismail, M., & Jafarzadeh Esfehani, A. (2019). Prevalence of Polycystic Ovary Syndrome among Malaysian Female University Staff. Journal of Midwifery and Reproductive Health, 7(1). https://doi.org/10.22038/jmrh.2018.30370.1329
3. Davinelli, S., Nicolosi, D., Di Cesare, C., Scapagnini, G., & Di Marco, R. (2020). Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review. Journal of Clinical Medicine, 9(4), 987. https://doi.org/10.3390/jcm9040987
4. Hoeger, K. M., Dokras, A., & Piltonen, T. (2021). Update on PCOS: Consequences, Challenges, and Guiding Treatment. The Journal of Clinical Endocrinology & Metabolism, 106(3), e1071–e1083. https://doi.org/10.1210/clinem/dgaa839
5. Kim, J. J., & Choi, Y. M. (2013). Dyslipidemia in women with polycystic ovary syndrome. Obstetrics & Gynecology Science, 56(3), 137–142. https://doi.org/10.5468/ogs.2013.56.3.137
6. Parker, J., Briden, L., & Gersh, F. L. (2025). Recognizing the Role of Insulin Resistance in Polycystic Ovary Syndrome: A Paradigm Shift from a Glucose-Centric Approach to an Insulin-Centric Model. Journal of Clinical Medicine, 14(12), 4021. https://doi.org/10.3390/jcm14124021